Literature DB >> 31186848

HCV infection on-treatment viral kinetics: Do they still have a role?

Jordan J Feld1.   

Abstract

Entities:  

Year:  2012        PMID： 31186848      PMCID： PMC6499260          DOI： 10.1002/cld.36

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  19 in total

Review 1.  Peginterferon and ribavirin for chronic hepatitis C.

Authors:  Jay H Hoofnagle; Leonard B Seeff
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

2.  Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.

Authors:  Donald M Jensen; Timothy R Morgan; Patrick Marcellin; Paul J Pockros; K Rajender Reddy; Stephanos J Hadziyannis; Peter Ferenci; Andrew M Ackrill; Bernard Willems
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

3.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

Authors:  Alessandra Mangia; Rosanna Santoro; Nicola Minerva; Giovanni L Ricci; Vito Carretta; Marcello Persico; Francesco Vinelli; Gaetano Scotto; Donato Bacca; Mauro Annese; Mario Romano; Franco Zechini; Fernando Sogari; Fulvio Spirito; Angelo Andriulli
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

4.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.

Authors:  Narendra M Dixit; Jennifer E Layden-Almer; Thomas J Layden; Alan S Perelson
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 6.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Authors:  Jordan J Feld; Jay H Hoofnagle
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

7.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Authors:  Peter Ferenci; Hermann Laferl; Thomas-Matthias Scherzer; Michael Gschwantler; Andreas Maieron; Harald Brunner; Rudolf Stauber; Martin Bischof; Bernhard Bauer; Christian Datz; Karin Löschenberger; Elisabeth Formann; Katharina Staufer; Petra Steindl-Munda
Journal:  Gastroenterology       Date:  2008-05-27       Impact factor: 22.682

9.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Authors:  Mitchell L Shiffman; Fredy Suter; Bruce R Bacon; David Nelson; Hugh Harley; Ricard Solá; Stephen D Shafran; Karl Barange; Amy Lin; Ash Soman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2007-07-12       Impact factor: 91.245

10.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.